内分泌薬の世界市場2021年-2025年

◆英語タイトル:Global Endocrinology Drugs Market 2021-2025
◆商品コード:IRTNTR40785
◆発行会社(リサーチ会社):Technavio
◆発行日:2021年5月26日
◆ページ数:約120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:北米、ヨーロッパ、アジア、その他
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

テクナビオ社は、内分泌薬の世界市場規模が2021年から2025年まで年平均6%以上成長し、252.5億ドルに達すると予測しています。本調査レポートでは世界の内分泌薬市場を調査対象とし、エグゼクティブサマリー、市場状況、市場規模、ファイブフォース分析、治療領域別(診断薬、hGH、甲状腺ホルモン障害、その他)分析、顧客状況、地域別状況、企業状況、企業分析など、以下の項目でまとめております。
・エグゼクティブサマリー
・市場状況
・市場規模
・ファイブフォース分析
・内分泌薬の世界市場規模:治療領域別(診断薬、hGH、甲状腺ホルモン障害、その他)
・顧客状況
・地域別状況
・企業状況
・企業分析
【レポートの概要】

Global Endocrinology Drugs Market 2021-2025

Technavio has been monitoring the endocrinology drugs market and it is poised to grow by $ 25.25 bn during 2021-2025, progressing at a CAGR of over 6% during the forecast period. Our report on endocrinology drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increase in the incidence of endocrine disorders and promising pipeline for endocrinology. In addition, an increase in the incidence of endocrine disorders is anticipated to boost the growth of the market as well.

The endocrinology drugs market analysis includes therapy area segment and geographic landscape.
Technavio’s endocrinology drugs market is segmented as below:

By Therapy Area
• Diabetes drugs
• hGH
• Thyroid hormone disorders
• Others

By Geography
• North America
• Europe
• Asia
• ROW

This study identifies the research in novel dosage formulations and drug delivery systems as one of the prime reasons driving the endocrinology drugs market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on endocrinology drugs market covers the following areas:
• Endocrinology drugs market sizing
• Endocrinology drugs market forecast
• Endocrinology drugs market industry analysis

Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading endocrinology drugs market vendors that include Acerus Pharmaceuticals Corp., Beta Cell NV, Eli Lilly and Co., GlaxoSmithKline Plc, Ipsen Pharma SA, Merck and Co. Inc., Novartis AG, Novo Nordisk AS, Pfizer Inc., and Sanofi SA. Also, the endocrinology drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors. For further information on this report, please visit – https://www.technavio.com/report/endocrinology-drugs-market-industry-analysis

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

【レポートの目次】

• Executive Summary
o Market Overview
• Market Landscape
o Market ecosystem
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2020
o Market outlook: Forecast for 2020 – 2025
• Five Forces Analysis
o Five forces summary
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by Therapy area
o Market segments
o Comparison by Therapy area
o Diabates drugs – Market size and forecast 2020-2025
o hGH – Market size and forecast 2020-2025
o Thyroid hormone disorders – Market size and forecast 2020-2025
o Others – Market size and forecast 2020-2025
o Market opportunity by Therapy area
• Customer landscape
o Customer landscape
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o North America – Market size and forecast 2020-2025
o Europe – Market size and forecast 2020-2025
o Asia – Market size and forecast 2020-2025
o ROW – Market size and forecast 2020-2025
o Key leading countries
o Market opportunity by geography
o Market drivers
o Market challenges
o Market trends
• Vendor Landscape
o Vendor landscape
o Landscape disruption
o Competitive Scenario
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o Acerus Pharmaceuticals Corp.
o Beta Cell NV
o Eli Lilly and Co.
o GlaxoSmithKline Plc
o Ipsen Pharma SA
o Merck and Co. Inc.
o Novartis AG
o Novo Nordisk AS
o Pfizer Inc.
o Sanofi SA
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations

Exhibits
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 3
• 4: Key Finding 5
• 5: Key Finding 6
• 6: Key Finding 7
• 7: Key Finding 8
• 8: Parent market
• 9: Market characteristics
• 10: Offerings of vendors included in the market definition
• 11: Market segments
• 12: Global – Market size and forecast 2020 – 2025 ($ million)
• 13: Global market: Year-over-year growth 2020 – 2025 (%)
• 14: Five forces analysis 2020 & 2025
• 15: Bargaining power of buyers
• 16: Bargaining power of suppliers
• 17: Threat of new entrants
• 18: Threat of substitutes
• 19: Threat of rivalry
• 20: Market condition – Five forces 2020
• 21: Other1 – Market share 2020-2025 (%)
• 22: Comparison by Other1
• 23: Diabates drugs – Market size and forecast 2020-2025 ($ million)
• 24: Diabates drugs – Year-over-year growth 2020-2025 (%)
• 25: hGH – Market size and forecast 2020-2025 ($ million)
• 26: hGH – Year-over-year growth 2020-2025 (%)
• 27: Thyroid hormone disorders – Market size and forecast 2020-2025 ($ million)
• 28: Thyroid hormone disorders – Year-over-year growth 2020-2025 (%)
• 29: Others – Market size and forecast 2020-2025 ($ million)
• 30: Others – Year-over-year growth 2020-2025 (%)
• 31: Market opportunity by Other1
• 32: Customer landscape
• 33: Market share by geography 2020-2025 (%)
• 34: Geographic comparison
• 35: North America – Market size and forecast 2020-2025 ($ million)
• 36: North America – Year-over-year growth 2020-2025 (%)
• 37: Europe – Market size and forecast 2020-2025 ($ million)
• 38: Europe – Year-over-year growth 2020-2025 (%)
• 39: Asia – Market size and forecast 2020-2025 ($ million)
• 40: Asia – Year-over-year growth 2020-2025 (%)
• 41: ROW – Market size and forecast 2020-2025 ($ million)
• 42: ROW – Year-over-year growth 2020-2025 (%)
• 43: Key leading countries
• 44: Market opportunity by geography ($ million)
• 45: Impact of drivers and challenges
• 46: Vendor landscape
• 47: Landscape disruption
• 48: Industry risks
• 49: Vendors covered
• 50: Market positioning of vendors
• 51: Acerus Pharmaceuticals Corp. – Overview
• 52: Acerus Pharmaceuticals Corp. – Business segments
• 53: Acerus Pharmaceuticals Corp. – Key offerings
• 54: Acerus Pharmaceuticals Corp. – Key customers
• 55: Acerus Pharmaceuticals Corp. – Segment focus
• 56: Beta Cell NV – Overview
• 57: Beta Cell NV – Product and service
• 58: Beta Cell NV – Key offerings
• 59: Beta Cell NV – Key customers
• 60: Beta Cell NV – Segment focus
• 61: Eli Lilly and Co. – Overview
• 62: Eli Lilly and Co. – Business segments
• 63: Eli Lilly and Co. – Key offerings
• 64: Eli Lilly and Co. – Key customers
• 65: Eli Lilly and Co. – Segment focus
• 66: GlaxoSmithKline Plc – Overview
• 67: GlaxoSmithKline Plc – Business segments
• 68: GlaxoSmithKline Plc – Key offerings
• 69: GlaxoSmithKline Plc – Key customers
• 70: GlaxoSmithKline Plc – Segment focus
• 71: Ipsen Pharma SA – Overview
• 72: Ipsen Pharma SA – Business segments
• 73: Ipsen Pharma SA – Key offerings
• 74: Ipsen Pharma SA – Key customers
• 75: Ipsen Pharma SA – Segment focus
• 76: Merck and Co. Inc. – Overview
• 77: Merck and Co. Inc. – Business segments
• 78: Merck and Co. Inc. – Key offerings
• 79: Merck and Co. Inc. – Key customers
• 80: Merck and Co. Inc. – Segment focus
• 81: Novartis AG – Overview
• 82: Novartis AG – Business segments
• 83: Novartis AG – Key offerings
• 84: Novartis AG – Key customers
• 85: Novartis AG – Segment focus
• 86: Novo Nordisk AS – Overview
• 87: Novo Nordisk AS – Business segments
• 88: Novo Nordisk AS – Key offerings
• 89: Novo Nordisk AS – Key customers
• 90: Novo Nordisk AS – Segment focus
• 91: Pfizer Inc. – Overview
• 92: Pfizer Inc. – Business segments
• 93: Pfizer Inc. – Key offerings
• 94: Pfizer Inc. – Key customers
• 95: Pfizer Inc. – Segment focus
• 96: Sanofi SA – Overview
• 97: Sanofi SA – Business segments
• 98: Sanofi SA – Key offerings
• 99: Sanofi SA – Key customers
• 100: Sanofi SA – Segment focus
• 101: Currency conversion rates for US$
• 102: Research Methodology
• 103: Validation techniques employed for market sizing
• 104: Information sources
• 105: List of abbreviations



【掲載企業】

Acerus Pharmaceuticals Corp., Beta Cell NV, Eli Lilly and Co., GlaxoSmithKline Plc, Ipsen Pharma SA, Merck and Co. Inc., Novartis AG, Novo Nordisk AS, Pfizer Inc., Sanofi SA

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[内分泌薬の世界市場2021年-2025年]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆